"サノフィ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonNovavax delays profitability target with eyes on Sanofi-led launches - Reuters
Novavax delays profitability target with eyes on Sanofi-led launches Reuters
Examining Sanofi’s Valuation After Immunology Pipeline Expansion and New Strategic Partnership - ...
Examining Sanofi’s Valuation After Immunology Pipeline Expansion and New Strategic Partnership Yahoo Finance
‘We chase the miracles of science so you can chase your dreams’: Sanofi unveils new global campai...
‘We chase the miracles of science so you can chase your dreams’: Sanofi unveils new global campaign Medical Marketing and Media
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $2...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent - GlobeNewswire
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent GlobeNewswire
Sanofi’s Growth Outlook Gains Ground With Berenberg Backing - Finimize
Sanofi’s Growth Outlook Gains Ground With Berenberg Backing Finimize
ESMO 2025 – Sanofi takes aim at Lutathera | ApexOnco - Clinical Trials news and analysis - Oncolo...
ESMO 2025 – Sanofi takes aim at Lutathera | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales - Fierce Pharma
For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales Fierce Pharma
Are Sanofi Shares Offering Hidden Value After Pipeline Expansion News in 2025? - simplywall.st
Are Sanofi Shares Offering Hidden Value After Pipeline Expansion News in 2025? simplywall.st
Patient Engagement: Informing & Empowering Patients - Sanofi
Novavax completes US marketing transfer to Sanofi for COVID vaccine - Investing.com
Novavax completes US marketing transfer to Sanofi for COVID vaccine Investing.com
Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales - BioPharma Dive
Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales BioPharma Dive
Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue - The Wall Street Journal
Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue The Wall Street Journal
Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off - Fierce Biotech
Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off Fierce Biotech
A Look at Novavax's Valuation Following U.S. Vaccine Rights Transfer to Sanofi (NVAX) - Yahoo Fin...
A Look at Novavax's Valuation Following U.S. Vaccine Rights Transfer to Sanofi (NVAX) Yahoo Finance
Sanofi notes 'negative buzz' around vaccines as profit beats forecasts - Reuters
Sanofi notes 'negative buzz' around vaccines as profit beats forecasts Reuters
Sanofi drug acquired in buyout succeeds in rare disease trial - BioPharma Dive
Sanofi drug acquired in buyout succeeds in rare disease trial BioPharma Dive
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launch...
Sanofi SA (SNY) Q3 2025 Earnings Call Highlights: Strong Growth Driven by DUPIXENT and New Launches Yahoo Finance
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement - Yahoo Finance
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement Yahoo Finance
Sanofi And Regeneron's Dupixent Meets Endpoints, Accepted For Priority Review By FDA - TradingView
Sanofi And Regeneron's Dupixent Meets Endpoints, Accepted For Priority Review By FDA TradingView
Sanofi inks $500M deal with Evoq for next-gen autoimmune tech - Fierce Biotech
Sanofi inks $500M deal with Evoq for next-gen autoimmune tech Fierce Biotech
Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure - Fierce Biotech
Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure Fierce Biotech
Sanofi Ventures bets on AI with $625m cash influx - - Global Corporate Venturing
Sanofi Ventures bets on AI with $625m cash influx - Global Corporate Venturing
Novavax Transfers Nuvaxovid Rights to Sanofi - TipRanks
Sanofi and Regeneron's Dupixent meets endpoints, accepted for priority review by FDA - MarketScre...
Sanofi and Regeneron's Dupixent meets endpoints, accepted for priority review by FDA MarketScreener
Sanofi (SNY) Shares Encouraging Phase 3 Results for Dupixent in AFRS Patients - GuruFocus
Sanofi (SNY) Shares Encouraging Phase 3 Results for Dupixent in AFRS Patients GuruFocus
[CIIE] France's Sanofi Debuts Two Cardiovascular Drugs, Deepening China Partnership - Yicai Global
[CIIE] France's Sanofi Debuts Two Cardiovascular Drugs, Deepening China Partnership Yicai Global
Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue - Investor's Busine...
Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue Investor's Business Daily
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Imp...
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Yahoo Finance
Sanofi (ENXTPA:SAN) Valuation: Is the Pharma Giant Trading Below Its True Worth? - simplywall.st
Sanofi (ENXTPA:SAN) Valuation: Is the Pharma Giant Trading Below Its True Worth? simplywall.st
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 a...
Sanofi sheds $13 billion in value on weak trial results for eczema drug - Reuters
Sanofi sheds $13 billion in value on weak trial results for eczema drug Reuters
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results - GuruFocus
REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results GuruFocus
Sanofi stock slides on Dupixent successor AD trial - Clinical Trials Arena
Sanofi stock slides on Dupixent successor AD trial Clinical Trials Arena
Sanofi Joins With EVOQ in $500M Autoimmune Alliance - BioSpace
Sanofi Joins With EVOQ in $500M Autoimmune Alliance BioSpace
ESMO 2025 preview – Sanofi’s lead shot gets a boost | ApexOnco - Clinical Trials news and analysi...
ESMO 2025 preview – Sanofi’s lead shot gets a boost | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Sanofi Shares Rebound 6% as Investors Weigh New Valuation Amid Pipeline Progress - Yahoo Finance
Sanofi Shares Rebound 6% as Investors Weigh New Valuation Amid Pipeline Progress Yahoo Finance
NANOBODY® Technology Platform - Sanofi
Sanofi gets one thumbs-up, one thumbs-down from Europe's CHMP - Fierce Pharma
Sanofi gets one thumbs-up, one thumbs-down from Europe's CHMP Fierce Pharma
Digital Transformation and Artificial Intelligence - Sanofi
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chroni...
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Yahoo Finance
Does Revvity’s (RVTY) Sanofi Partnership and Expanded T1D Diagnostics Shift Its Long-Term Growth ...
Does Revvity’s (RVTY) Sanofi Partnership and Expanded T1D Diagnostics Shift Its Long-Term Growth Outlook? Yahoo Finance
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older ad...
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots - BioSpace
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots BioSpace
Environmental Impact and Healthcare Systems’ Resilience - Sanofi
Environmental Impact and Healthcare Systems’ Resilience Sanofi
Novavax Completes Nuvaxovid US Marketing Authorization Transfer to Sanofi - MarketScreener
Novavax Completes Nuvaxovid US Marketing Authorization Transfer to Sanofi MarketScreener
Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development - Fierc...
Why Sanofi's R&D chief is 'pretty pragmatic' about a 'mixed' year of clinical development Fierce Biotech
Sanofi set to offer insulin products at $35 per month for all US patients - Reuters
Sanofi set to offer insulin products at $35 per month for all US patients Reuters
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal (NASDAQ:SNY) - Seeking Alpha
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal (NASDAQ:SNY) Seeking Alpha
Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study - TipRanks
Sanofi, Regeneron report all primary endpoints met in LIBERTY-AFRS-AIMS study TipRanks
Sanofi comes up against a graft-versus-host disease rock | ApexOnco - Clinical Trials news and an...
Sanofi comes up against a graft-versus-host disease rock | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
A Million Conversations: Bridging Trust Gap - Sanofi
Why Is Sanofi Stock Falling Thursday? - Yahoo Finance
Why Is Sanofi Stock Falling Thursday? Yahoo Finance
Sanofi Ventures banks $625M to back young biotechs, digital health startups - BioPharma Dive
Sanofi Ventures banks $625M to back young biotechs, digital health startups BioPharma Dive
Novavax - FDA approves transfer of Nuvaxovid authorization to Sanofi - SEC filing - MarketScreener
Novavax - FDA approves transfer of Nuvaxovid authorization to Sanofi - SEC filing MarketScreener
Sanofi shares drop after disappointing trial results - statnews.com
Sanofi shares drop after disappointing trial results statnews.com
FDA Extends Review Time for Sanofi’s BTK Inhibitor Tolebrutinib - NeurologyLive
FDA Extends Review Time for Sanofi’s BTK Inhibitor Tolebrutinib NeurologyLive
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces...
Genomic Medicine Unit: Overcoming Gene Therapy’s Greatest Challenges - Sanofi
Genomic Medicine Unit: Overcoming Gene Therapy’s Greatest Challenges Sanofi
Sanofi phase 3 eczema win falls short of analyst expectations - Fierce Biotech
Sanofi phase 3 eczema win falls short of analyst expectations Fierce Biotech
Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues - Fi...
Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues Fierce Biotech
Sustainability: Building a Healthier World - Sanofi
Sanofi juices up biotech investment arm with $625M cash infusion - Fierce Biotech
Sanofi juices up biotech investment arm with $625M cash infusion Fierce Biotech
French court orders Sanofi to pay $177 million for anti-competitive behaviour - Reuters
French court orders Sanofi to pay $177 million for anti-competitive behaviour Reuters
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others - BioSpace
FDA Hands Out First Commissioner’s Priority Vouchers to Regeneron, Sanofi, Disc, Others BioSpace
Press Release: Sanofi’s SAR446268 earns US fast track - GlobeNewswire
Press Release: Sanofi’s SAR446268 earns US fast track GlobeNewswire
US FDA approves Sanofi's drug for a rare blood disorder - Reuters
US FDA approves Sanofi's drug for a rare blood disorder Reuters
Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline - Reuters
Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Reuters
Sanofi says under investigation by European Commission over vaccines - Reuters
Sanofi says under investigation by European Commission over vaccines Reuters
Berenberg Upbeat on Sanofi's Top Line Growth, R&D Turnaround - MarketScreener
Berenberg Upbeat on Sanofi's Top Line Growth, R&D Turnaround MarketScreener
Sanofi pipeline shines with multiple deals and clinical progress - Labiotech.eu
Sanofi pipeline shines with multiple deals and clinical progress Labiotech.eu
Sanofi's German, French premises hit by EU probe amid vaccines market abuse concerns - Fierce Pharma
Sanofi's German, French premises hit by EU probe amid vaccines market abuse concerns Fierce Pharma
Novavax delays profitability target with eyes on Sanofi-led launches - MSN
Novavax delays profitability target with eyes on Sanofi-led launches MSN
Voices in ITP Care: The Power of Shared Decision-Making - Sanofi
Voices in ITP Care: The Power of Shared Decision-Making Sanofi
Sanofi stops supply of high cholesterol drug to China due to limited availability - Reuters
Sanofi stops supply of high cholesterol drug to China due to limited availability Reuters
Sanofi's $110M radioligand therapy hits response rate goal in phase 2 tumor trial - Fierce Biotech
Sanofi's $110M radioligand therapy hits response rate goal in phase 2 tumor trial Fierce Biotech
Don’t delegate the AI revolution: A conversation with Sanofi CEO Paul Hudson - McKinsey & Company
Don’t delegate the AI revolution: A conversation with Sanofi CEO Paul Hudson McKinsey & Company
Sanofi CEO: AI might beat IQ, not EQ — but never say never - Fortune
Sanofi CEO: AI might beat IQ, not EQ — but never say never Fortune
Novavax Announces Progress on Sanofi Agreement - Yahoo Finance
Novavax Announces Progress on Sanofi Agreement Yahoo Finance
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Yahoo Finance
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline Yahoo Finance
Sanofi commits ‘at least $20bn’ to US manufacturing through 2030 - Pharmaceutical Technology
Sanofi commits ‘at least $20bn’ to US manufacturing through 2030 Pharmaceutical Technology
Press Release: Sanofi’s Tzield accepted for expedited - GlobeNewswire
Press Release: Sanofi’s Tzield accepted for expedited GlobeNewswire
Sanofi's OX40L Inhibitor Amlitelimab Shows Positive Results in Phase 3 AD Trial - Dermatology Times
Sanofi's OX40L Inhibitor Amlitelimab Shows Positive Results in Phase 3 AD Trial Dermatology Times
Sanofi exploring vaccine production in Vietnam with local partner - Reuters
Sanofi exploring vaccine production in Vietnam with local partner Reuters
Sanofi sees 'manageable' impact from US tariffs, expects strong sales growth - Reuters
Sanofi sees 'manageable' impact from US tariffs, expects strong sales growth Reuters
France's Sanofi to acquire biotech firm Vicebio for $1.15 billion - Reuters
France's Sanofi to acquire biotech firm Vicebio for $1.15 billion Reuters
Sanofi hops on the US investment bandwagon with $20B commitment through 2030 - Fierce Pharma
Sanofi hops on the US investment bandwagon with $20B commitment through 2030 Fierce Pharma
With FDA nod, Sanofi's Wayrilz becomes 1st US BTK drug approved for immune thrombocytopenia - Fie...
With FDA nod, Sanofi's Wayrilz becomes 1st US BTK drug approved for immune thrombocytopenia Fierce Pharma
Sanofi: Information concerning the total number of voting rights and shares - August 2025 - Yahoo...
Sanofi: Information concerning the total number of voting rights and shares - August 2025 Yahoo Finance
Sanofi expands $35-per-month pricing to all insulin products - Fierce Pharma
Sanofi expands $35-per-month pricing to all insulin products Fierce Pharma
Sanofi Rings the Closing Bell - Nasdaq
US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies ...
US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies Reuters
Sanofi Modulus: The Best Inventions of 2025 - Time Magazine
Sanofi Modulus: The Best Inventions of 2025 Time Magazine
Sanofi Joins Growing Group of Pharmas Pulling Back From UK - BioSpace
Sanofi Joins Growing Group of Pharmas Pulling Back From UK BioSpace
Sanofi Announces Positive Phase 2a Results for Brivekimig in HS - Dermatology Times
Sanofi Announces Positive Phase 2a Results for Brivekimig in HS Dermatology Times
Sustainable and Equitable Access to Healthcare - Sanofi
Sanofi slides 9% as key pipeline asset misses expectations in dermatitis study - FirstWord Pharma
Sanofi slides 9% as key pipeline asset misses expectations in dermatitis study FirstWord Pharma
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout -...
Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout MedTech Dive
Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay - Fierce Biotech
Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay Fierce Biotech
Leerink Partners Maintains a Buy Rating on Sanofi (SNY) - Yahoo Finance
Leerink Partners Maintains a Buy Rating on Sanofi (SNY) Yahoo Finance